Sight Sciences, Inc. (NASDAQ:SGHT) EVP Manohar K. Raheja Buys 4,624 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Manohar K. Raheja bought 4,624 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were bought at an average price of $3.99 per share, with a total value of $18,449.76. Following the purchase, the executive vice president now owns 102,624 shares in the company, valued at $409,469.76. The trade was a 4.72 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sight Sciences Price Performance

Shares of NASDAQ SGHT traded down $0.16 during mid-day trading on Tuesday, reaching $3.86. 102,699 shares of the company were exchanged, compared to its average volume of 200,215. The stock has a market capitalization of $195.93 million, a PE ratio of -3.78 and a beta of 2.58. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 52 week low of $2.58 and a 52 week high of $8.45. The company’s 50 day moving average price is $5.09 and its 200 day moving average price is $6.07.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The firm had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. Sell-side analysts forecast that Sight Sciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on SGHT. Lake Street Capital cut shares of Sight Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $10.00 to $5.00 in a research note on Monday, November 4th. Morgan Stanley cut their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, November 11th. Piper Sandler restated a “neutral” rating and issued a $5.50 target price (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Sight Sciences presently has a consensus rating of “Hold” and an average price target of $5.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Steele Capital Management Inc. purchased a new stake in Sight Sciences during the 2nd quarter valued at $67,000. SG Americas Securities LLC bought a new position in shares of Sight Sciences during the third quarter valued at about $75,000. The Manufacturers Life Insurance Company bought a new stake in shares of Sight Sciences in the second quarter worth about $95,000. GSA Capital Partners LLP bought a new position in Sight Sciences during the 3rd quarter valued at approximately $136,000. Finally, American Century Companies Inc. lifted its holdings in Sight Sciences by 31.1% in the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after buying an additional 8,527 shares during the period. Institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.